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Myc is a transcription factor whose ability to activate cell growth and DNA replication is tightly 
regulated in healthy cells. When Myc is deregulated (e.g., through overexpression), its activity can 
lead to genomic instability, uncontrolled growth and ultimately cancer. There are multiple cellular 
mechanisms in place to trigger apoptosis in response to aberrant Myc activity (e.g., Myc-induced 
DNA damage may activate apoptotic pathways via the tumor suppressor p53). Unfortunately, many 
aggressive human cancers frequently harbor concurrent genetic changes that disable these 
pathways (e.g., inactivating mutations in p53). It is thus of great interest that research technician 
Russell Moser, principal investigator Dr. Carla Grandori and colleagues in the Human Biology 
Division have identified a mechanism for reducing cancer development in the context of both Myc 
overexpression and p53 inactivation. 
Grandori and colleagues previously found that Myc activates the transcription of WRN, a DNA 
helicase/exonuclease that repairs DNA replication errors. In the absence of WRN, Myc 
overexpressing cells are driven to senescence through DNA damage sensing pathways. These 
findings led Moser et al. to investigate whether silencing of WRN could inhibit the development of 
Myc-driven tumors in vivo. Using two different mouse models of cancer, they showed that silencing 
of WRN leads to a) reduced tumor growth in xenografts of a human lung cancer cell line that 
expresses high levels of Myc and b) increased median survival of mice that rapidly develop 
lymphomas due to constitutive Myc expression in lymphoid precursor cells (115 days compared to 
151 days if WRN is inactivated at the germ-line). Moreover, the authors found significantly higher 
levels of a DNA damage marker, reduced levels of proliferation and no signs of increased apoptosis 
in the WRN silenced models compared to controls. This trend held true even after stratifying for p53 
mutations in late onset lymphomas from the second mouse model. Taken together, these results 
suggest that WRN may be a valuable therapeutic target for cancers driven by Myc-deregulation, 
including those that exhibit p53 mutations. 
What, then, is the consequence of WRN inhibition in humans? Nature has already performed this 
experiment, as individuals suffering from Werner Syndrome possess inactivating mutations in WRN. 
These individuals exhibit accelerated aging, cellular senescence, and genetic instability, and also  
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suffer from rare types of cancer. In contrast, WRN deficient mice are not predisposed to 
spontaneous tumor development. These two seemingly contradictory observations may be 
explained by the delayed onset of Werner Syndrome, which is approximately 15 years in humans. 
Short term WRN inhibition for cancer therapy might thus preclude Werner Syndrome like effects, and 
anyway, such effects may be worth the risk to individuals suffering from aggressive Myc-driven 
cancers. For example, neuroblastoma cases are already screened for Myc overexpression, as this 
phenotype is associated with more aggressive cancer. 
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In mice that developed tumors from xenografts of a human 
lung cancer cell line expressing high levels of Myc, treatment 
with an shRNA against the WRN DNA repair helicase to 
downregulate WRN expression (shWRN) significantly 
stunted tumor growth compared to treatment with a negative 
control shRNA (Control). * p < 0.05 
 
